Fighting Prostate Cancer's Survival Mechanisms

Dr. Kim Chi (1999 Research Grant)

Cancer cells are extremely adaptable and can mutate to resist treatments. For example, cancer cells make a protein called clusterin which resists hormone therapy, radiation and other treatments. Mutations like clusterin make cancer difficult to treat.

In 1999 we awarded Dr. Kim Chi a grant to study a new clusterin-fighting drug. Called OGX-011, the drug his team developed contains genetically engineered material that inhibits the production of clusterin and leaves cancer cells vulnerable to radiation therapy.

Dr. Chi is now overseeing the clinical development of OGX-011. Early results from 72 patients were positive; the drug inhibited clustern in prostate cancer cells by more than 90 per cent. Phase II testing is now ongoing.




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Université de Sherbrooke Researchers’ Findings Published in Cancer Research

Sherbrooke, November 16, 2017 – Prostate cancer, the most common cancer in men, affects one out of seven Canadian men.
More

12 innovative Canadian prostate cancer researchers set out to make new Discoveries

Toronto, ON – September 28, 2017: 12 forward-thinking Canadian prostate cancer researchers have been rewarded for their innovation with Movember Discovery Grants.
More

Gray Tools '2017 Together We Are Stronger' campaign a success in creating awareness and raising funds for prostate cancer

BRAMPTON, Ontario, Sept 26, 2017 (GLOBE NEWSWIRE) -- Gray Tools Canada Inc, in cooperation with Prostate Cancer Canada, is proud to announce that its “2017 Together We Are Stronger” initiative raised $4,000, which will go directly towards funding valuable research that is needed to improve the way we diagnose, treat, and support men living with the disease.
More


Click here for news archive